News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
Jaguar Health and Napo Pharmaceuticals extend collaboration with Streeterville related to development of NP-300 drug product candidate for cholera patients, aiming for Tropical Disease Priority Review Voucher from FDA -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. founder Lisa Conte to present virtually at Emerging Growth Conference on Feb 18, 2025. Company focuses on sustainable pharmaceuticals derived from rainforest plants for gastrointestinal distress -
-
-
COMMUNIQUÉ DE PRESSE
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
Magdalena to submit IND application for psychoactive drug candidate for mental health indications. MB2500 aims to treat cognitive deficit in schizophrenia and ADHD. Magdalena focuses on safe, plant-based drugs under FDA Botanical Guidance -
